-
The IND application filed by partner IOVaxis Therapeutics to initiate TG01 clinical development in
China was approved by the Chinese NMPA on1 March 2024 -
Following IND approval, IOVaxis has an option to exercise an exclusive license for Circio's TG mutant RAS cancer vaccine program for
Greater China andSingapore
Under the parties' agreement, IOVaxis has an exclusive option to license mutant RAS cancer vaccines TG01 and TG02 for
For further information, please contact:
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Phone: +47 922 61 624
Email: renate.birkeli@circio.com
About Circio
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare disease, vaccines, and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in
https://news.cision.com/circio/r/the-tg01-ind-application-by-circio-s-partner-iovaxis-therapeutics-has-been-approved-by-the-chinese-r,c3940351
(c) 2024 Cision. All rights reserved., source